IL318680A - Pharmaceutical preparations and their uses for the treatment of glioma - Google Patents
Pharmaceutical preparations and their uses for the treatment of gliomaInfo
- Publication number
- IL318680A IL318680A IL318680A IL31868025A IL318680A IL 318680 A IL318680 A IL 318680A IL 318680 A IL318680 A IL 318680A IL 31868025 A IL31868025 A IL 31868025A IL 318680 A IL318680 A IL 318680A
- Authority
- IL
- Israel
- Prior art keywords
- glioma
- treatment
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370520P | 2022-08-05 | 2022-08-05 | |
| PCT/US2023/029534 WO2024030645A1 (en) | 2022-08-05 | 2023-08-04 | Pharmaceutical compositions and uses thereof for the treatment of glioma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318680A true IL318680A (en) | 2025-03-01 |
Family
ID=89849850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318680A IL318680A (en) | 2022-08-05 | 2023-08-04 | Pharmaceutical preparations and their uses for the treatment of glioma |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4565237A4 (de) |
| JP (1) | JP2025527300A (de) |
| KR (1) | KR20250056926A (de) |
| CN (1) | CN119997956A (de) |
| AU (1) | AU2023320122A1 (de) |
| CA (1) | CA3263675A1 (de) |
| IL (1) | IL318680A (de) |
| MX (1) | MX2025001423A (de) |
| WO (1) | WO2024030645A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4684834A1 (de) * | 2024-07-26 | 2026-01-28 | BRIU GmbH | Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008302345A1 (en) * | 2007-09-19 | 2009-03-26 | Oncofluor, Inc. | Method for imaging and treating organs and tissues |
| HUE068623T2 (hu) | 2011-04-29 | 2025-01-28 | Penn State Res Found | Normál és tumorsejtek kismolekulás TRAIL-génindukclója rákellenes terápiaként |
| US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| CA3131740A1 (en) * | 2019-02-27 | 2020-09-03 | Madera Therapeutics, LLC | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents |
| CN116437925A (zh) * | 2020-08-06 | 2023-07-14 | 厄特沃什罗兰科技大学 | 新的依米立酮衍生物的合成及其抗癌活性的评估 |
| WO2022031952A2 (en) * | 2020-08-07 | 2022-02-10 | City Of Hope | Treatments for cancers having kras mutations |
-
2023
- 2023-08-04 AU AU2023320122A patent/AU2023320122A1/en active Pending
- 2023-08-04 IL IL318680A patent/IL318680A/en unknown
- 2023-08-04 KR KR1020257007349A patent/KR20250056926A/ko active Pending
- 2023-08-04 JP JP2025506206A patent/JP2025527300A/ja active Pending
- 2023-08-04 CN CN202380070175.7A patent/CN119997956A/zh active Pending
- 2023-08-04 EP EP23850795.8A patent/EP4565237A4/de active Pending
- 2023-08-04 WO PCT/US2023/029534 patent/WO2024030645A1/en not_active Ceased
- 2023-08-04 CA CA3263675A patent/CA3263675A1/en active Pending
-
2025
- 2025-02-04 MX MX2025001423A patent/MX2025001423A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4565237A4 (de) | 2026-02-18 |
| WO2024030645A1 (en) | 2024-02-08 |
| KR20250056926A (ko) | 2025-04-28 |
| MX2025001423A (es) | 2025-07-01 |
| AU2023320122A2 (en) | 2025-08-14 |
| AU2023320122A1 (en) | 2025-02-20 |
| CA3263675A1 (en) | 2024-02-08 |
| CN119997956A (zh) | 2025-05-13 |
| JP2025527300A (ja) | 2025-08-20 |
| EP4565237A1 (de) | 2025-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202110597B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB202010464D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL286677A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| ZA202208630B (en) | Use of pharmaceutical composition for preventing and treating novel coronavirus pneumonia | |
| GB2613460B (en) | Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a | |
| IL308221A (en) | Preparations and methods for treating depression | |
| IL286688A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| GB201911868D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL312583A (en) | A preparation for the treatment and prevention of COVID-19 | |
| IL286685A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| IL318680A (en) | Pharmaceutical preparations and their uses for the treatment of glioma | |
| IL316049A (en) | Musuntuzumab pharmaceutical preparations and methods of use | |
| IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| GB201905711D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases | |
| HK40128040A (zh) | 药物组合物及其用於治疗胶质瘤的用途 | |
| IL319382A (en) | Pharmaceutical preparation and its use | |
| GB202406893D0 (en) | Therapeutic and preventive compositions | |
| GB202208022D0 (en) | Therapeutic compounds and compositions | |
| GB201907547D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B | |
| GB202001420D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| GB202001421D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL309355A (en) | The compositions and their use for the treatment of alpha 1-antitrypsin deficiency | |
| GB202110230D0 (en) | Compounds and pharmaceutical compositions for the treatment of metabolic disorders |